ClinicalTrials.gg
RecruitingNCT07102342NouvNeu001-01Updated May 11, 2026

This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.

A Phase 1/2 interventional study of Human Dopaminergic Progenitor Cells in Parkinson Disease, sponsored by iRegene Therapeutics Co., Ltd.. Recruiting at 1 site in United States. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by iRegene Therapeutics Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 386 under way, 7 of them phase 3. Parkinson Disease · United States.

Planned enrollment
1,170th of 1,256
5 · median 36
Started
2026
with 82 others
Phase 1/2
51 of 1,649
11 open now
Primary completion
2027-09
later than 207 of 383 live
Registered
1,542nd of 1,649
by date

Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 1,170th largest by planned enrollment of the 1,256 interventional ones that give a count, is one of 83 that started in 2026, is one of 51 in phase 1/2, reaches primary completion later than 207 of the 383 other live ones, and was the 1,542nd registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

299 more — sign in →

All 304 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,649 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

This is a phase 1/2 clinical study to evaluate the safety, tolerability, feasibility, and preliminary efficacy of NouvNeu001 in patients with advanced Parkinson's Disease.

Read the detailed description

This is a multi-center, single arm, and open label trial. The NouvNeu001 will be transplanted into the bilateral putamen/striatum using stereotactic neurosurgery. Subjects will take immunosuppressants to prevent potential immune rejection for 24 to 36 weeks.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • NouvNeu001
  • Human Dopaminergic Progenitor Cells Injection
  • phase 1 study
  • Dopaminergic Progenitor Cells
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age

  • Male or female patient must be 30 to 75 years of age inclusive, at the time of signing the form (ICF).

Type of Patient and Disease Characteristics

  • Diagnosis of PD between past 4 to 20 years (meet MDS 2015 clinical diagnostic criteria for PD).
  • H-Y staging (Appendix III) for "OFF" episodes is 2.5-4.0.
  • MDS-UPDRS-III score > 35, and positive for the Acute levodopa challenge test (ALCT) (improvement > 30% for MDS UPDRS-III staging from OFF episodes to ON episodes) over two screening period visits. Baseline scores will be computed as the means of two screening period visits.
  • No significant change in UPDRS-III scores between the two visits during the screening period.
  • Patients who take stable doing of dopamine drug for at least 4 weeks prior to receiving the study drug.
  • No significant change in dose and dosing schedule of the prescribed medicines for PD during the screening period.
  • Medically suitable for neurosurgery under general anesthesia.
  • Acceptable laboratory test values during screening and prior to transplantation (Day 0):

    • ≥ 2.0 × 109/L
    • White blood cell count ≥ 4.0 × 109/L
    • count ≥ 100 × 109/L
    • (AST) and alanine transaminase (ALT) ≤ 2.5 x (ULN)
    • Total ≤ 1.5 x ULN
    • Serum creatinine ≤ 1.5 x ULN
    • ≥ 50 mL/min/1.73 m2
  • Agree to postpone any additional neurosurgical procedures, including DBS, until completion of the 12-month follow-up study (unless recommended by a neurologist).
  • Agree not to participate in any other therapeutic intervention study within 24 months after neurosurgery.
  • Able to participate in all study visits and evaluations, including brain/spine MRI, CT and PET scan.

Weight • (BMI) within the range of 18\~32 kg/m2 (inclusive) with a minimum body weight of 45 kg at screening.

Sex and /Barrier Requirements

  • Contraceptive use by men and women for 12 months after neurosurgery should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Informed Consent

  • Able to understand the rationale of the clinical trial and sign the ICF. Other Inclusion Criteria
  • Agree not to receive COVID-19 vaccine within 14 days before neurosurgery, and not to receive any other vaccine within 30 days after neurosurgery

Exclusion criteria

Exclusion Criteria:

Medical Conditions

  • Atypical Parkinsonism (Parkinsonism-Plus syndrome, secondary parkinsonism, familial parkinsonism) Prior/Concomitant Therapy
  • Patients who have had previous pallidotomy, DBS surgery, striatal or extrapyramidal surgery, brain stereotaxy, prior surgical or radiation therapy to the brain or spinal cord, or other brain surgery; as well as other surgical procedures that, in the investigator's judgment, could interfere with participation in this study.
  • Patients who have a previous head CT/MRI examination showing cerebral trauma, vascular malformation, hydrocephalus, brain tumor, etc., and patients who have brain imaging abnormalities in the striatum or other brain areas leading to a significantly increased risk for surgery.
  • Patients who have had previous cellular therapy.
  • Patients who have used for an extended period (≥14 days) and at high doses (equivalent to prednisone ≥ 20 mg/day or other glucocorticoids at equivalent doses) within 3 months prior to signing the ICF. (excluding topical treatment)
  • Patients who have used drugs for an extended period (≥14 days) within 3 months prior to signing the ICF.
  • Patients who have used antipsychotics, such as antidepressants, antimanic drugs, etc. within 3 months prior to signing the ICF and are deemed by the investigator to potentially impact the study assessment.
  • Patients who have used botulinum toxin or other drugs for dystonia or muscle spasticity within 6 months prior to signing the ICF and are deemed by the investigator to potentially impact the study assessment.

Prior/Concurrent Clinical Study Experience

  • Patients who are participating in other clinical trials, or have been enrolled in other clinical studies within 3 months prior to the screening
  • Patients with poor compliance based on clinical evaluation of the investigator. Diagnostic Assessments
  • Patients with a history of dementia or a severe cognitive disorder; or those with obvious dementia or congnitive impairment detected during screening; MDS-UPDRS congnitive impairment score (section 1.1) > 3 point at screening; or patinets with poor compliance, inability to accurately keep diary, and/or inability to sign ICF due to dementia.
  • Severe depression as defined by HAMD ≥ 24 at screening.
  • Severe anxiety as defined by HAMA ≥ 29 at screening.
  • Patients with a history of psychiatric disorders that, in the investigator's opinion, make them unsuitable for participation; or patients with a history of suicidal ideation or suicide attempts within the past year or currently (including actual attempts, interrupted attempts, or failed attempts).
  • Patients with abnormal coagulation ( ≥ 1.5 , activated partial thromboplastin time ≥ 1.5 ULN), or abnormal INR at screening.
  • Patients cannot temporarily suspend anti- agents or other anti-coagulant medications at least 5 days prior to drug administration surgery.
  • Patients with active disseminated intravascular coagulation and significant hemorrhagic tendency within 3 months prior to signing the ICF.
  • Patients with current or history of following disease

    • severe heart failure (congestive heart failure of Class II or above), unstable angina pectoris, and myocardial infarction
    • severe arrhythmia, including but not limited to second- or third-degree atrioventricular block, or prolonged .
    • Long QT Syndrome.
    • cardiovascular surgery (cardiac, vascular stent surgery, angioplasty).
    • stroke or within 3 months prior to signing the ICF, as determined by the investigator to be unsuitable to participate the study.
    • subarachnoid hemorrhage
    • primary mitochondrial disorder, multiple sclerosis, or other neurodegenerative diseases such as Alzheimer's disease
    • major vascular diseases (aortic aneurysm, aortic dissecting aneurysm, internal carotid artery stenosis), as determined by the investigator to be unsuitable to participate the study.
    • previous or current malignant tumors
    • immune disfunction, including disease or immunocompromised state
    • traumatic brain injury with loss of consciousness and residue neurologic symptoms
    • active epilepsy or currently on anti-epileptic drugs
  • Hypertensive patients with poorly controlled blood pressure (defined as blood pressure above 160/100 mmHg despite antihypertensive drugs treatment) and patients with severe postural hypotension
  • Diabetic patients with poorly controlled blood glucose (glycosylated > 9.0%, or fasting plasma glucose (FPG) ≥ 11.1mmol/L)
  • Patients with abnormalities in kidney or liver function at screening.
  • Patient with clinically significant abnormalities in immunological tests at screening
  • Patients with surgical (such as those with cochlear implant, cardiac pacemaker, cardiac defibrillator, stereotactic nucleus pallidotomy; Patients who have had unilateral or bilateral intraparenchymal implantation of cellular products, or other surgical procedures within 6 months before screening which, in the opinion of the investigator, have an impact on this trial; Patients with other neurosurgical contraindications)
  • Patients with other combined severe systemic diseases, such as pulmonary heart disease, moderate to severe asthma, severe (COPD) (% \< 50%)
  • Patients with serious infections, requiring antibiotic treatment within 2 weeks prior to signing the ICF
  • Patients with any active infectious disease, including but not limited to positive for , SARS Covid-19 virus, syphilis antibody, quantitative testing, quantitative testing greater than normal range for test results, or untreated tuberculosis; any other active infection that, in the investigator's opinion, may affect the participant's ability to take part in the study or could impact study outcomes.

Other Exclusion Criteria

  • Patients with alcohol or drug addiction
  • Patients with contraindications or a history of allergy to any medicines used during the neurosurgical procedure.
  • Patients with contraindication or a history of allergy to any medicines used during the study, such as immunosuppressants, levodopa, etc, or any of their components; Patients who are allergic to similar drugs or other macrolides.
  • Female of who are not surgically sterilized/premenopausal/unwilling to use medically approved effective during the study and lactating women; men who are not surgically sterilized/unwilling to use medically approved effective contraception during the study
  • Patients who have received electric shock therapy within 30 days prior to the investigational drug administration surgery
  • Patients who are participating in other clinical trials, or have been enrolled in other clinical studies within 3 months prior to the screening
  • Patients with poor compliance based on clinical evaluation of the investigator
  • Patients who are being treated with drugs such as neuroleptics, apomorphine, or levodopa/carbidopa infusion therapy
  • Patients with severe dyskinesia in both "ON" and "OFF" drug states
  • Patients who have received or will receive a within 4 weeks prior to the study
  • Patients with significant medical conditions, or with other conditions that, in the opinion of the investigator, are unsuitable to participate in the study
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    NouvNeu001

    Single injection of Human Dopaminergic Progenitor Cells into the bilateral putamen/striatum regions of the brain.

    Biological: Human Dopaminergic Progenitor Cells

Interventions

  • BiologicalHuman Dopaminergic Progenitor Cells

    Single injection of Human Dopaminergic Progenitor Cells into the biliteral putamen/striatum regions of the brain

    Also known as: NouvNeu001

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).

    Time frame: 24 weeks and 48 weeks post-transplant

Secondary outcomes

  1. The Motor Function and Non-motor Function

    Changes in MDS-UPDRS Part I-IV Score from baseline to 48 weeks and 96 weeks post-transplant. A higher score indicates more severe symptoms or worse health.

    Time frame: 48 weeks and 96 weeks post-transplant

  2. Continued Safety and Tolerability

    Incidence and severity of AEs and SAEs within 96 weeks and 15 years post-transplant.

    Time frame: 96 weeks and 15 years post-transplant

07

Study locations

1 of 1 sites recruiting
  • Cornell University Weill Medical College
    New York, New York 10065, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Sep 2027, 20 months after the start.

Of 55 phase 1/2 interventional studies under Parkinson Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 53. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2025
First posted
Aug 3, 2025
StartActual
Jan 12, 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2032
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07102342
Lead sponsor
iRegene Therapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Aug 3, 2025
Start date
Jan 12, 2026
Primary completion
Sep 2027 (estimated)
Completion
Sep 2032 (estimated)
Last update
May 11, 2026

Study contacts

Meng Cai, Ph.D
Contact
caimeng@iregene.com
0086-027-59337986
Jing Zhao, PhD
Contact
zhaojing@iregene.com

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion